Atrial natriuretic peptide
Cardiac peptide hormone; heart failure research.
What it is
Atrial natriuretic peptide (ANP, also called atrial natriuretic factor or ANF) is a 28-amino-acid peptide hormone produced primarily by atrial cardiomyocytes in response to atrial wall stretch. It is part of the natriuretic peptide family that also includes BNP (brain natriuretic peptide, despite the name primarily produced in cardiac tissue), CNP (C-type natriuretic peptide, primarily endothelial), and others.
ANP was discovered in the early 1980s and represented a paradigm shift in cardiovascular biology — recognition that the heart functions as an endocrine organ producing peptide hormones with significant cardiovascular and renal effects. A synthetic version (carperitide) is approved in Japan for acute decompensated heart failure but has not received FDA approval in the US.
Mechanism of action
ANP acts through natriuretic peptide receptor A (NPR-A), producing:
- Vasodilation: reduces vascular tone in arterial and venous beds
- Diuresis and natriuresis: increases sodium and water excretion through renal effects
- Suppression of renin-angiotensin-aldosterone system
- Modulation of sympathetic nervous system tone
- Anti-fibrotic effects in cardiac and vascular tissue
Clinical evidence
ANP and related natriuretic peptides have been extensively studied in heart failure contexts. Recombinant BNP (nesiritide) was FDA-approved for acute decompensated heart failure but use has declined. ANP itself (carperitide) is used in Japan for similar indications. Outpatient or chronic use of natriuretic peptides has not been established.
Why we don’t prescribe it at The Tide
Atrial natriuretic peptide is not appropriate for outpatient peptide clinic use. The peptide’s primary applications are in acute hospital cardiology contexts (acute decompensated heart failure) where IV administration and intensive monitoring are required. The Tide does not provide acute cardiac care.
Side effects and contraindications
Hypotension is the most significant side effect — sometimes severe. Renal effects can be problematic in patients with renal impairment. IV administration requires cardiac monitoring. Not appropriate for outpatient use.